Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Partners Group Private Equity

    MCap

    EUR734m

    Last close

    EUR10.60

    ▲ 907.60 (8,726.92%)

    SenSen Networks

    MCap

    AUD55m

    Last close

    AUD0.10

    ▲ 0.03 (37.68%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Ocugen (OCGN)

Last close As at 05/09/2025

USD1.03

— 0.00 (0.00%)

Market capitalisation

USD302m

Ocugen is a clinical-stage biotechnology company developing novel gene therapies to treat blinding retinal diseases, and its subsidiary is advancing cell therapies for orthopaedic indications.

Latest Insights

Healthcare | Non client QV

Ocugen — Novel cell therapies for retinal diseases
Visit Website

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Shankar Musunuri

    CEO

  • Ramesh Ramachandran

    Chief Accounting Officer

Research

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development

thematic

Healthcare

Outlook for 2023: Biotechs remain central to novel drug development
Cancer cells

thematic

Healthcare

Oncology ABCs (part four): Blood cancers (AML) – notable innovations
cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

Edison healthcare quarterly: How to please some of the people some of the time